ClinicalTrials.gg
CompletedNCT00886600Updated Aug 27, 2015Results posted

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

A Phase 3 interventional study of losartan potassium and Comparator: placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
27th of 65
122 · median 100
Started
1991
with 1 other
Phase 3
17 of 65
1 open now
Registered
18th of 65
by date
Lead sponsor
6 of 65
Merck Sharp & Dohme LLC

Among the 65 studies testing losartan in Hypertension, this one is the 27th largest by enrollment, is one of 2 that started in 1991, is one of 17 in phase 3, and was the 18th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring (ABPM), and to evaluate the safety of losartan 50 and 100 mg doses compared to placebo.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-black men and women with mild to moderate hypertension and within 30% of their ideal body weight
  • Patient is in good general health
  • Blood pressure at time of randomization is 95-115 mm Hg

Exclusion criteria

Exclusion Criteria:

  • Secondary Hypertension or history of malignant hypertension
  • History of stroke
  • History of myocardial infarction
  • Atrial flutter or atrial fibrillation
  • History of congestive Heart failure
  • Patient taking major psychotropic agent or anti-depressant
  • Patient regularly uses NSAIDS or high dose aspirin
  • Known positive test for /AIDS or
  • Patient is being treated for acute ulcer disease
  • Prior exposure to losartan
  • Actively treated diabetes mellitus
  • History of chronic liver disease
  • Actively treated diabetes mellitus
  • Any known bleeding or disorder
  • Absence of one kidney
  • Women of
  • Alcoholism or drug addiction
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Comparator: placebo · Drug: hydrochlorothiazide (HCTZ)

  • Experimental
    2

    losartan 50 mg q.d.

    Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)

  • Experimental
    3

    losartan 100 mg q.d.

    Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)

  • Experimental
    4

    losartan 50 mg b.i.d.

    Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)

Interventions

  • losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks

    Also known as: MK0954

  • DrugComparator: placebo

    placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks

  • open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks

    Also known as: HCTZ

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4

    Time frame: 24 hour period at Baseline and Week 4

  2. Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4

    Time frame: 24-hour period at baseline and Week 4

Secondary outcomes

  1. Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4

    Time frame: Baseline and 24-hours after morning dose at Week 4

  2. Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6

    Time frame: Baseline and 24-hours after morning dose at Week 6

  3. Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6

    Time frame: Baseline and 24-hours after morning dose at Week 6

07

Results

Posted Jul 14, 2009
Limitations and caveats
Safety has been reported in the literature.

Participant flow

Patients were recruited at 9 sites in the United States. Prime Therapy Period: May, 1991 to March, 1992.

Double-blind Monotherapy
Participant flow — Double-blind Monotherapy
MilestonePlacebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mg
Started32293031
Completed30282929
Not completed2112
Withdrew: Adverse event1111
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject1000
Combination Therapy Period
Participant flow — Combination Therapy Period
MilestonePlacebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mg
Started28212123
Completed28211923
Not completed0020
Withdrew: Adverse event0010
Withdrew: Protocol violation0010

Outcome measures

PrimaryMean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
Time frame:
24 hour period at Baseline and Week 4
Reported as:
Mean · mm Hg
Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
mm HgPlacebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mg
Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4-0.2 ± 4.8-5.2 ± 5.1-6.4 ± 5.5-8.5 ± 6.7
PrimaryMean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
Time frame:
24-hour period at baseline and Week 4
Reported as:
Mean · mm Hg
Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
mm HgPlacebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mg
Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 40 ± 7.8-9.2 ± 9.9-9.9 ± 7.6-13.2 ± 10.6
SecondaryMean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4
Time frame:
Baseline and 24-hours after morning dose at Week 4
Reported as:
Mean · mm Hg
Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4
mm HgPlacebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mg
Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4-2.1 ± 6.9-6.7 ± 7.8-9.6 ± 6.5-8.8 ± 7.8
SecondaryMean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6
Time frame:
Baseline and 24-hours after morning dose at Week 6
Reported as:
Mean · mm Hg
Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6
mm HgPlacebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mg
Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6-4.6 ± 6.1-9.9 ± 6.3-10.7 ± 4.9-10.1 ± 7.8
SecondaryMean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6
Time frame:
Baseline and 24-hours after morning dose at Week 6
Reported as:
Mean · mm Hg
Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6
mm HgPlacebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mg
Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6-4.0 ± 6.4-5.1 ± 7.8-4.0 ± 6.1-4.0 ± 6.9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mgTotal
Mean52.2 ± 12.056.8 ± 12.151.2 ± 9.654.1 ± 9.053.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mgTotal
Female71091339
Male2519211883
Race/Ethnicity
Race/Ethnicity(participants)Placebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mgTotal
Caucasian30293030119
Oriental00011
Filipino10001
Indian10001
Diastolic 24-hr mean ambulatory blood pressure monitoring (ABPM)
Diastolic 24-hr mean ambulatory blood pressure monitoring (ABPM)(mm Hg)Placebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mgTotal
Mean94.8 ± 5.994.0 ± 6.993.8 ± 6.094.4 ± 6.994.2 ± 6.4
Sitting Diastolic Blood Pressure (SiDBP)
Sitting Diastolic Blood Pressure (SiDBP)(mm Hg)Placebo / HCTZ 12.5 mgLosartan 50 mg q.d. / HCTZ 12.5 mgLosartan 100 mg q.d. / HCTZ 12.5 mgLosartan 50 mg b.i.d. / HCTZ 12.5 mgTotal
Mean100.7 ± 4.0100.0 ± 4.6101.5 ± 5.1101.2 ± 4.8100.9 ± 4.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995 Feb 27;155(4):405-11. Erratum In: Arch Intern Med 1995 Apr 24;155(8):876. PubMed 7848024 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 1991, a primary completion of May 1992 and a completion of Aug 1992. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 17 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2009
First posted
Apr 23, 2009
Start
May 1991
Primary completionActual
May 1992
CompletionActual
Aug 1992
Results first posted
Jul 14, 2009
Last update
Aug 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00886600
Responsible party
Sponsor
First posted
Apr 23, 2009
Start date
May 1991
Primary completion
May 1992
Completion
Aug 1992
Results posted
Jul 14, 2009
Last update
Aug 27, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion